Innovation Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program; Topline Results Anticipated Early Q1 2020

NEXT STORY
Generex Biotechnology Provides 2019 Year-End Summary & 2020 Plans
PREV STORY
The global LFIA based rapid test market was valued at $4,725 million in 2018, and is projected to reach $8,494 million by 2026, registering a CAGR of 7.6% from 2019 to 2026
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

TELUS and Koodo Giving Two Months Free Wireless Service to Frontline Hospital Workers in Ontario

author_avatar
NASDAQ Market News

Surgical Care Affiliates Partners With The Surgery Center at Doral

DEERFIELD, Ill., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Surgical Care Affiliates, Inc. (NASDAQ:SCAI) (“SCA”), ...

author_avatar
NASDAQ Market News

Study of BioAegis’ Lead Product, Gelsolin, is Key Component of NIAID Strategic Plan for COVID-19 Research

author_avatar
NASDAQ Market News